论文部分内容阅读
目的探讨辛伐他汀对慢性血栓栓塞性肺动脉高压(chronic thromboembolic pulmonary hypertension,CTEPH)患者血浆纤溶酶原激活物抑制剂-1(plasminogen activator inhibitor-1,PAI-1)活性的影响。方法 CTEPH患者分别服用10、20、40mg/天辛伐他汀7、14、21d后,用PAI-1发色底物法检测血浆PAI-1活性。结果与对照组相比,CTEPH组血浆PAI-1水平明显增高;辛伐他汀呈剂量依赖性降低CTEPH患者血浆PAI-1水平。结论辛伐他汀可降低CTEPH患者血浆PAI-1水平。
Objective To investigate the effect of simvastatin on plasma plasminogen activator inhibitor-1 (PAI-1) in patients with chronic thromboembolic pulmonary hypertension (CTEPH). Methods Patients with CTEPH were treated with simvastatin 10, 20 and 40 mg / d for 7, 14, and 21 days, respectively. PAI-1 activity was detected by PAI-1 chromogenic substrate assay. Results Plasma levels of PAI-1 in CTEPH group were significantly higher than those in control group. Simvastatin decreased PAI-1 level in CTEPH patients in a dose-dependent manner. Conclusion Simvastatin can reduce plasma PAI-1 level in patients with CTEPH.